News

Stay up to date with Avenzo on our mission to develop next-generation oncology therapies to transform cancer treatment.

Year:

  • All
  • 2026
  • 2025
  • 2024
  • 2023

Type:

  • Press Releases
  • Avenzo in the News
  • Events & Presentations
  • Corporate Presentation

Avenzo Therapeutics Corporate Presentation – Nov 2026

View Presentation

Avenzo Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in London

November 9, 2026

view

2026 Jefferies Global Healthcare Conference in London

November 18, 2026

view

Stifel 2026 Healthcare Conference

November 11, 2026

view

Guggenheim 3rd Annual Healthcare Innovation Conference

November 10, 2026

view

Avenzo Therapeutics to Participate at Upcoming Investor Conferences

November 3, 2026

view

Avenzo Therapeutics to Present Preliminary Phase 1 Results from ORION-1 Study of AVZO-023, a Selective CDK4 Inhibitor, at the 2026 San Antonio Breast Cancer Symposium

October 30, 2026

view

Avenzo Therapeutics Announces Oral Presentation of Phase 1 Data for VBC103 (AVZO-103), a Potentially Differentiated Nectin-4/TROP2 Bispecific Antibody-Drug Conjugate, by Partner VelaVigo at ESMO Asia Congress 2026

October 13, 2026

view

Avenzo Therapeutics Appoints Herb Cross as Incoming Chief Financial Officer

October 5, 2026

view

Avenzo Therapeutics Expands Leadership Team

September 28, 2026

view

Avenzo Therapeutics to Present Preliminary Phase 1 Study Results of AVZO-1418, a Potentially Differentiated EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium

September 10, 2026

view

Avenzo Therapeutics Announces Appointment of Barbara Bodem and Elizabeth Mily to Board of Directors as Independent Directors

September 3, 2026

view

Avenzo Therapeutics to Participate in the Upcoming Wells Fargo 21st Annual Healthcare Conference

September 2, 2026

view

Wells Fargo 21st Annual Healthcare Conference

September 9, 2026

view view

Avenzo Therapeutics Announces Appointment of Connie Wedel as Chief Human Resources Officer

August 24, 2026

view

Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting

June 1, 2026

view

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

June 1, 2026

view

Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study

May 28, 2026

view

Avenzo Therapeutics Advances the Combination of CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) in Ongoing Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer

April 28, 2026

view

Avenzo Therapeutics to Present Updated Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting

April 21, 2026

view

Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium

December 11, 2025

view

Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin

November 24, 2025

view

Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer

November 19, 2025

view

Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC

November 10, 2025

view

Avenzo Therapeutics to Present Initial Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium

October 30, 2025

view

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

September 29, 2025

view

Avenzo Therapeutics Announces $60 Million Series B Financing

September 22, 2025

view

Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

September 2, 2025

view

Avenzo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate

July 8, 2025

view

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-023, a Potential Best-in-Class, Novel CDK4 Selective Inhibitor

June 5, 2025

view

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate

June 3, 2025

view

Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate

May 22, 2025

view

Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-023 (ARTS-023), a Potential Best-in-Class, Novel CDK4 Selective Inhibitor

May 21, 2025

view

Exclusive: Avenzo picks up another ADC, this time with multi-partnered DualityBio

January 7, 2025 • Source: Endpoints News

view

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate

January 7, 2025

view

Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director

November 20, 2024

view

Avenzo Therapeutics Provides Corporate Update and Announces Closing of Series A/A-1 Financing

November 18, 2024

view

Exclusive: Athena Countouriotis’ Avenzo taps Shanghai biotech for ADC, adds new funds

November 18, 2024 • Source: Endpoints News

view

Avenzo Therapeutics Honored by Goldman Sachs for Entrepreneurship

October 16, 2024

view

Avenzo Therapeutics Announces Appointment of Garry Nicholson to Board of Directors as Independent Director

October 1, 2024

view

Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer

September 3, 2024

view

For Chinese biotechs, the out-licensing business is scorching hot. Could geopolitics rain on their parade?

April 11, 2024 • Source: Fierce Biotech

view

Exclusive: Athena Countouriotis’ Avenzo nabs $150M to in-license more assets

March 26, 2024 • Source: Endpoints News

view

Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline

March 26, 2024

view

Exclusive: After Turning Point success, oncology vets in-license first asset for Avenzo Therapeutics

January 4, 2024 • Source: Endpoints News

view

Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics

January 4, 2024

view

How biotech deal-making really works behind the scenes, according to founders

October 20, 2023 • Source: STAT News

view

Handful of biotechs expected to IPO this fall, but many are stuck in ‘holding pattern’ until 2024

August 30, 2023 • Source: Endpoints News

view

Ex-Turning Point execs plan to have their next bet, Avenzo, on the Nasdaq next summer

May 26, 2023 • Source: Endpoints News

view

Turning Point team quietly reforms at Avenzo, raises $196M

May 25, 2023 • Source: BioCentury

view

NASDAQ: In Conversation With Avenzo

April 19, 2023 • Source: Nasdaq

view